NeurogesX Inc (fka NGSX)

[surf1944]

7:30AM Neurogesx provides update on NGX-1998 clinical program: end of Phase 2 meeting with FDA expected in Q3 (NGSX) 0.39 : Co announced that the FDA has accepted the co's request for an End-of-Phase 2 meeting to discuss the continued clinical investigation of NGX-1998 as a treatment for certain neuropathic pain conditions including, specifically, the Company's plans for entering NGX-1998 into Phase 3 development. The Company anticipates that the End-of-Phase 2 meeting will occur in the third quarter of 2012.